Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 8Active not recruiting 7Completed 3Terminated 2Suspended 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Burkitt Lymphoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

pembrolizumab 116Carboplatin 46Nivolumab 45Paclitaxel 34Cyclophosphamide 34Cisplatin 32Gemcitabine 30atezolizumab 28Specimen Handling 26venetoclax 25Magnetic Resonance Spectroscopy 24Docetaxel 24fludarabine 23Pemetrexed 23Biopsy 22Bevacizumab 22Radiotherapy 21Ipilimumab 21Azacitidine 21Dexamethasone 19durvalumab 18Radiosurgery 18Fluorouracil 17Cetuximab 16Trastuzumab 15fludarabine phosphate 14Leucovorin 14Cytarabine 14tislelizumab 13Lenalidomide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × azathiopurine × 1 year × Clear all
NCT05032183 2025-08-11

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
4 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02420717 2025-06-08

Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 2 Terminated
11 enrolled 13 charts
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡